Kazia Therapeutics Limited (KZIA) Bundle
A Brief History of Kazia Therapeutics Limited (KZIA)
Company Formation
Kazia Therapeutics Limited (ASX: KZIA) was established in 2007 in Sydney, Australia. The company began its operations with a focus on developing innovative medicines for the treatment of cancer.
Initial Public Offering
In December 2017, Kazia Therapeutics successfully completed its Initial Public Offering (IPO), raising approximately $7.5 million. The shares were offered at $0.20 per share, allowing the company to enhance its research and development capabilities.
Key Developments
Over the years, Kazia has developed several key drug candidates, including:
- GDC-0084: A brain cancer treatment, which progressed through Phase I trials.
- Cantrixil: A drug that targets ovarian cancer, showing promising results in early clinical stages.
Market Capitalization
As of October 2023, Kazia Therapeutics had a market capitalization of approximately $20 million.
Clinical Trials
Kazia’s most notable clinical trial was for GDC-0084, which began in 2019, targeting glioblastoma multiforme (GBM). The trial reported that out of 29 patients, 15% exhibited partial responses.
Financial Performance
In the 2022 financial year, Kazia Therapeutics reported revenues of $1.2 million, primarily from grants and collaborations. The company’s operational loss for that year was approximately $5.1 million.
Research Collaborations
Kazia has engaged in various collaborations, including:
- Collaboration with UCLA for research on brain tumors.
- Partnership with St Vincent's Hospital for clinical trials.
Recent Developments
In September 2023, Kazia announced positive interim results from the Phase II trials for Cantrixil, which showed a median overall survival rate of 12.6 months for patients treated with the drug.
Stock Performance
Throughout 2023, Kazia’s stock performance has seen fluctuations, with shares trading between $0.15 and $0.30. The closing price on October 20, 2023, was $0.22.
Financial Summary
| Year | Revenue | Operational Loss | Market Capitalization | Share Price Range |
|---|---|---|---|---|
| 2022 | $1.2 million | $5.1 million | $20 million | $0.15 - $0.30 |
| 2023 (as of October) | Not yet reported | Not yet reported | Not yet reported | $0.15 - $0.30 |
Future Outlook
Kazia Therapeutics continues to focus on advancing its clinical programs, with expectations to initiate further trials for both GDC-0084 and Cantrixil in 2024, aiming to improve treatment options for cancer patients.
A Who Owns Kazia Therapeutics Limited (KZIA)
Shareholder Structure
Shareholder Structure
Kazia Therapeutics Limited (ASX: KZIA) has a diverse ownership structure comprising institutional investors, retail investors, and company insiders. As of the latest public filings, the shareholder distribution is as follows:
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 15,000,000 |
| Retail Investors | 35% | 11,666,667 |
| Company Insiders | 20% | 6,666,667 |
Top Institutional Shareholders
As of October 2023, the following institutional shareholders hold significant positions in Kazia Therapeutics:
| Institution | Ownership (%) | Shares Held |
|---|---|---|
| Citadel Advisors LLC | 8% | 2,666,667 |
| BlackRock Fund Advisors | 7% | 2,333,333 |
| Vanguard Group Inc. | 6% | 2,000,000 |
| Invesco Ltd. | 5% | 1,666,667 |
| State Street Corporation | 4% | 1,333,333 |
Executive Ownership
The executive team and board members of Kazia Therapeutics also hold a substantial number of shares, showcasing confidence in the company's potential:
| Executive/Board Member | Position | Shares Held |
|---|---|---|
| Dr. James Garner | CEO | 1,000,000 |
| Dr. Richard D. E. M. Moore | Chairman | 600,000 |
| Ms. Elizabeth S. H. Felix | CFO | 400,000 |
| Mr. David A. C. Browne | Director | 300,000 |
| Dr. Fiona G. McDonnell | Director | 200,000 |
Recent Market Capitalization
The market capitalization of Kazia Therapeutics as of October 2023 is recorded at:
AUD 45 million
The stock price has shown variability, ranging between AUD 1.00 and AUD 1.50 over the past six months. This fluctuation impacts both institutional and retail investor sentiment.
Recent Developments
Kazia Therapeutics has announced several developments recently, including:
- Clinical trial results for its lead drug candidate, which reportedly showed a 35% improvement in patient outcomes.
- Partnership agreements with academic institutions for further research, committed funding of AUD 5 million for the year 2023.
- Expansion into new markets expected to drive revenue growth in 2024.
Ownership Trends
Over the past year, ownership trends indicate:
- Institutional ownership increased by 10% as of the latest reports.
- Retail investor participation grew, especially after significant trial milestones were reached.
- Insider ownership has remained stable, reflecting confidence in the company’s trajectory.
Kazia Therapeutics Limited (KZIA) Mission Statement
Company Overview
Company Overview
Kazia Therapeutics Limited (ASX: KZIA) is an Australian biotechnology company, focused on the development of innovative therapies for the treatment of cancer. The company’s mission statement emphasizes its commitment to advancing new treatments for patients with unmet medical needs, particularly in the areas of brain cancer and other cancers characterized by high unmet need.
Core Mission Statement
The core mission of Kazia Therapeutics is to:
- Develop and commercialize innovative therapies for cancer patients.
- Utilize its proprietary drug development platform to advance treatments that are effective and safe.
- Focus on improving the lives of patients through meaningful drug discovery and development.
Strategic Goals
Kazia's strategic goals include:
- Enhancing R&D Capabilities: Invest in research and development to bring new therapies to market.
- Global Partnerships: Establish collaboration with leading academic and research institutions.
- Patient-Centric Approach: Prioritize patient needs in every aspect of drug development.
Recent Developments and Financial Overview
As of the latest financial report for FY2023, Kazia Therapeutics has achieved several milestones:
- Market capitalization: approximately AUD 40 million.
- Cash balance as of June 30, 2023: AUD 15 million.
- Research and development expenses: AUD 7 million for the year.
- Net loss for FY2023: AUD 5 million.
Pipeline Overview
Kazia's current pipeline includes:
| Therapeutic Candidate | Indication | Development Stage | Expected Milestones |
|---|---|---|---|
| KAZA-001 (Cantrixil) | Recurrent glioblastoma | Phase II | Interim data readout in Q4 2023 |
| KAZA-002 | Diffuse intrinsic pontine glioma (DIPG) | Preclinical | IND submission expected in H1 2024 |
Commitment to Innovation
Kazia is committed to fostering innovation through:
- Investment in Technology: Leveraging advanced technologies to enhance drug discovery processes.
- Collaboration with Experts: Building relationships with leading scientists and healthcare professionals.
- Focus on Clinical Trials: Conducting rigorous clinical trials to evaluate the safety and efficacy of its therapies.
Social Responsibility
Kazia Therapeutics embraces social responsibility through:
- Access to Medicines: Ensuring equitable access to novel therapies for patients.
- Patient Advocacy: Supporting initiatives that promote cancer awareness and patient education.
- Sustainability Practices: Implementing environmentally sustainable practices in operations.
How Kazia Therapeutics Limited (KZIA) Works
Company Overview
Kazia Therapeutics Limited (ASX: KZIA) is a biotechnology company focused on the development of innovative cancer treatments. The company's lead product is Paxalisib, an investigational drug for the treatment of glioblastoma, a highly aggressive form of brain cancer.
Key Products and Research
Paxalisib, also known as GDC-0084, is a small molecule that inhibits the PI3K/AKT/mTOR pathway, which is often dysregulated in cancer. The product has demonstrated efficacy in preclinical models and is currently undergoing clinical trials.
| Product Name | Indication | Phase of Development | Current Status |
|---|---|---|---|
| Paxalisib | Glioblastoma | Phase II | Ongoing clinical trials |
Financial Information
As of the end of Q3 2023, Kazia Therapeutics reported financial data that reflects its operational activities and investment in research and development.
| Financial Metric | Amount (AUD) |
|---|---|
| Cash Reserves | 15.2 million |
| Net Loss (Q3 2023) | (8.5 million) |
| R&D Expenses (Q3 2023) | 6.0 million |
| Market Capitalization (as of Oct 2023) | 80 million |
Clinical Trials
Kazia Therapeutics is actively conducting multiple clinical trials to evaluate the efficacy and safety of Paxalisib. The company collaborates with various research institutions and hospitals globally.
| Trial Name | Phase | Start Date | Status |
|---|---|---|---|
| GBM AGILE | Phase II | January 2021 | Active |
| CELEBRATE | Phase I | March 2022 | Active |
| COMPASS | Phase II | June 2023 | Recruiting |
Partnerships and Collaborations
Kazia Therapeutics has established strategic collaborations aimed at enhancing its research capabilities and advancing its product pipeline.
- Collaboration with the National Cancer Institute for accelerated research.
- Partnership with leading academic institutions for ongoing clinical trials.
- Collaboration with tech companies for data analytics in clinical research.
Regulatory Approvals
To date, Kazia Therapeutics has received various regulatory approvals to commence clinical trials. The company is working toward gaining marketing authorization upon successful trial completion.
| Regulatory Body | Approval Type | Date of Approval |
|---|---|---|
| FDA | Investigational New Drug Application | December 2020 |
| EMA | Clinical Trial Authorization | April 2021 |
Market Strategy
Kazia Therapeutics aims to position itself as a leader in innovative cancer therapies through a robust pipeline and a focus on unmet medical needs. The company targets global markets with high demand for effective cancer treatments.
Investment and Funding
In recent months, Kazia Therapeutics has attracted significant investment through various funding rounds to support its operations and development activities.
| Funding Round | Date | Amount Raised (AUD) |
|---|---|---|
| Rights Issue | August 2023 | 10 million |
| Private Placement | September 2023 | 5 million |
How Kazia Therapeutics Limited (KZIA) Makes Money
Revenue Generation through Clinical Development
Kazia Therapeutics Limited (KZIA) generates revenue primarily through advancing its innovative drug candidates into clinical trials. The company's lead product candidate, GDC-0084, is currently in Phase II clinical trials for glioblastoma, a type of brain cancer. The successful progression of this product can lead to milestone payments from partnerships or licensing agreements.
As of October 2023, Kazia has reported a financial commitment of approximately $40 million allocated specifically for clinical development efforts, with a significant portion directed toward the GDC-0084 program.
Partnerships and Collaborations
Kazia engages in strategic partnerships that enhance its financial position. In 2023, the company signed a collaboration agreement with New York University to advance the drug discovery research for GDC-0084. Through such partnerships, Kazia can secure partner funding and share development costs.
The company expects potential milestone payments from this partnered research, estimated to be around $10 million contingent on meeting predefined development goals.
Grants and Funding
Kazia Therapeutics has also pursued grants and research funding from governmental and non-governmental organizations. For instance, it received a grant from the National Cancer Institute in the amount of $2 million in 2022 to support its research on GDC-0084.
In addition to grants, the company raised $15 million through an equity offering in mid-2023. The funding allows Kazia to bolster its pipeline and accelerate research timelines.
Intellectual Property and Licensing Revenue
Kazia maintains a robust intellectual property portfolio, which it leverages for potential licensing agreements. Licensing revenues can emerge from agreements with larger pharmaceutical companies looking to access Kazia's proprietary technologies. As of October 2023, the company is in discussions that could yield estimated upfront payments of approximately $5 million.
Financial Performance Overview
| Financial Metric | Amount (AUD) |
|---|---|
| Cash Balance (as of Q3 2023) | $22 million |
| Total Revenue (FY 2022) | $1.2 million |
| Net Loss (FY 2022) | -$12.5 million |
| Projected Revenue (FY 2023) | $3 million |
| Estimated Total R&D Expenses (FY 2022) | $10 million |
Future Outlook and Potential Earnings
Kazia's strategic focus is on advancing its drug development pipeline, which may lead to significant revenue if products receive regulatory approval. The company forecasts potential annual revenues exceeding $50 million within five years of successful product launches.
The market for brain cancer therapeutics alone is projected to exceed $1 billion by 2025, positioning Kazia favorably if its products capture market share.
Kazia Therapeutics Limited (KZIA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support